Sensei Biotherapeutics, Inc. announced that topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), will be presented in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 ? June 4, 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.7554 USD | -9.75% | -47.90% | +9.16% |
May. 14 | Stephens Starts Sensei Biotherapeutics With Overweight Rating, $5 Price Target | MT |
May. 09 | Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.16% | 18.94M | |
+8.92% | 114B | |
+10.48% | 105B | |
-2.94% | 21.73B | |
-6.45% | 23.83B | |
-10.70% | 18.1B | |
-42.36% | 16.34B | |
-14.45% | 16.13B | |
+3.76% | 13.75B | |
+28.94% | 11.76B |
- Stock Market
- Equities
- SNSE Stock
- News Sensei Biotherapeutics, Inc.
- Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting